MAP2K7 and heart failure: Patient factors that may predispose to BRAF/MEK inhibitor–associated cardiotoxicity include pre-existing cardiovascular disease (prior heart failure/cardiomyopathy, ischemic heart disease, and severe valvular heart disease) as well as advancing age and other conventional cardiovascular risk factors such as hypertension, diabetes mellitus, chronic kidney disease, and cigarette smoking.